Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) has announced its participation in three upcoming investor conferences focused on healthcare. The events include the Jefferies Global Healthcare Conference on June 9, 2022, the Goldman Sachs Annual Global Healthcare Conference on June 14, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022. Presentations will be available via webcast and can be re-watched on the company's website. Madrigal is developing treatments for non-alcoholic steatohepatitis (NASH), with its leading candidate, resmetirom, currently in Phase 3 trials.

CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor conferences:

Jefferies Global Healthcare Conference
3:00 PM ET on Thursday, June 9, 2022.

Goldman Sachs Annual Global Healthcare Conference
11:40 AM ET on Tuesday, June 14, 2022.

JMP Securities Life Sciences Conference
10:00 AM ET on Wednesday, June 15, 2022.

The presentations will be webcast and archived recordings will be available for replay in the Investors & Media section of the Madrigal website after the events.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com 

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com 

FAQ

What are the dates for the upcoming investor conferences for Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 9, 2022, the Goldman Sachs Annual Global Healthcare Conference on June 14, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022.

How can I access the webcasts of Madrigal Pharmaceuticals' presentations?

The presentations from Madrigal Pharmaceuticals' investor conferences will be available via webcast and can be re-watched in the Investors & Media section of their official website.

What is Madrigal Pharmaceuticals' lead candidate for NASH?

Madrigal Pharmaceuticals' lead candidate for treating non-alcoholic steatohepatitis (NASH) is resmetirom, which is currently being evaluated in two Phase 3 clinical studies.

What is the purpose of Madrigal's participation in investor conferences?

Madrigal Pharmaceuticals participates in investor conferences to update stakeholders about their clinical developments, including ongoing trials for their novel therapeutics targeting NASH.

Where can I find more information about Madrigal Pharmaceuticals?

More information about Madrigal Pharmaceuticals can be found on their official website at www.madrigalpharma.com.